Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ta-NPs Combined With Radiotherapy for Locally Recurrent Retroperitoneal Soft Tissue Sarcoma
NCT07578506Phase 1Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of tantalum nanoparticles in retroperitoneal soft tissue sarcoma (RPS) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Dose-Limiting Toxicity at 28 days. Planned start May 2026; status: not yet recruiting.
02
Drugs
tantalum nanoparticles
03
Conditions
retroperitoneal soft tissue sarcoma (RPS)
Beyond the preview
Go deeper on NCT07578506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07578506.